Navigation Links
Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
Date:11/6/2008

SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, today announced that data relevant to betrixaban, the company's novel oral Factor Xa inhibitor and PRT060128, its novel ADP receptor antagonist, will be presented at the American Heart Association (AHA) Scientific Sessions 2008. The conference will be held at the Ernest N. Morial Convention Center in New Orleans, LA during November 8-12, 2008.

"We have important data being presented at AHA that demonstrate the potential of our differentiated Phase II compounds that address major unmet needs in preventing and treating thrombosis," said Charles Homcy, M.D., president and chief executive officer of Portola. "In particular, data from Dr. Paul Gurbel show how our antiplatelet agent may be effective in a high percentage of patients who do not respond adequately to clopidogrel, the current standard of care. Additionally, data being presented will show that our two Phase II agents, PRT060128 and betrixaban, our oral once-daily FXa inhibitor, may work in combination to inhibit thrombosis without raising bleeding risk. Together these data highlight some of the unique properties of our lead antithrombotic compounds."

Following are the details on each poster presentation.

Monday, November 10

Poster Title: "Combination of Direct Acting FXa Inhibitor and P2Y12

Antagonist at Non-Effective Doses Provides Significant Inhibition of

Arterial Thrombosis"

Patrick Andre et al

Time: 9:00 a.m. - 5:00 p.m.

Hall A-B1, Poster Board B129

Wednesday, November 12

Poster Title: "Oral Dosing of PRT060128, a Novel Direct-acting,

Reversible P2Y12 Antagonist Overcomes High Platelet Reactivity in

Patients Non-responsive to Clopidogrel Therapy"

Paul A. Gurbel et al

Time: 9:00 a.m. - 5:00 p.m.

Hall A-B1, Poster Board C6

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concept that are engineered to provide significant advances over current treatments for cardiovascular and inflammatory diseases and cancer.

Portola's two lead Phase II compounds, betrixaban, an oral Factor Xa inhibitor and PRT060128, an ADP receptor antagonist, target the global multi- billion dollar antithrombotic market. Both product candidates have best-in- class features versus current and novel agents in development and address the hospital, specialty, and chronic care markets. The Company's earlier-stage programs are leveraging its chemistry and kinase expertise to develop specific Syk and JAK inhibitors to treat cancer and inflammatory diseases with broader activity. The company also has a novel anticoagulant antidote program with the potential to help manage the more than 20 million patients expected to be treated with anticoagulants worldwide in the next decade. For additional information, visit http://www.portola.com.


'/>"/>
SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
2. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
3. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
4. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
5. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
6. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
7. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
8. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
9. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
10. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
11. Lutonix Inc. Announces $20 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2017)... , May 12, 2017  The China and Canada ... technology that consumes less water, energy and detergent, and features a ... product LaughingU, a shoebox-sized washing machine that washes and sanitizes women,s ... ... LaughingU, is compact, and does not require an external water inlet. ...
(Date:5/10/2017)... Global Health Intelligence (GHI), the leading healthcare data analytics ... 2017 ranking of the Best-Equipped Hospitals in Latin America ... GHI,s hospitals database for Latin America , which is ... database covers 86% of the hospitals in Latin ... each institution in key areas such as beds, medical specialties, ...
(Date:5/10/2017)... GLEN BURNIE, Md. , May 10, 2017 /PRNewswire/ ... and retention solutions for the clinical research industry, is ... website, www.CSSiEnroll.com . The new website features both ... better overall user experience and enhances the company,s already ... in the industry. "After many months ...
Breaking Medicine Technology:
(Date:5/28/2017)... ... ... HYPERAMS, LLC announced it will perform the inventory liquidation of ... The sale began this week and the inventory is expected to sell quickly. ... medical accessories, including blood pressure cuffs, stethoscopes, CPR masks, as well as blank polos, ...
(Date:5/27/2017)... (PRWEB) , ... May 27, 2017 , ... Hate visiting the dentist? You should go ... need to take care of your teeth at home. Here are some dental tips to ... meals. Keep a small toothbrush in your work desk or a locker at school for ...
(Date:5/26/2017)... ... May 26, 2017 , ... The ... to review more than eighty-nine grant submissions all vying for nearly $1,000,000 in ... the Parkinson’s field.     , The American Parkinson Disease Association (APDA) is focused on ...
(Date:5/26/2017)... ... ... A new analysis of community health data reveals that four out of the ... the average cost of healthcare rising and the U.S. senior population expected to double ... of where they live. An annual 2017 report looked at a variety of community ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Yisrayl Hawkins, Pastor ... publication this week that is focusing on the Peace Agreements being discussed by President ... East sprint in a race to try to speed up peace talks in the ...
Breaking Medicine News(10 mins):